AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03895242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2:Prone-Supine
Description: After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
Study NCT02015533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single 2-hour intravenous infusion.
Study NCT00636714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing judgement
Description: Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
Study NCT00636714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nomogram
Description: A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
Study NCT01968161 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Asenapine
Study NCT01719861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine HCL
Description: Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 30 mg
Description: TAK-792 30 mg was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 30 mg placebo
Description: TAK-792 30 mg placebo was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 100 mg
Description: TAK-792 100 mg was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 100 mg placebo
Description: TAK-792 100 mg placebo was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 250 mg
Description: TAK-792 250 mg was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 250 mg placebo
Description: TAK-792 250 mg placebo was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 500 mg
Description: TAK-792 500 mg was administered in the morning after a fast or after breakfast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 500 mg placebo
Description: TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 750 mg
Description: TAK-792 750 mg was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 750 mg placebo
Description: TAK-792 750 mg placebo was administered in the morning after a fast.
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 1250 mg
Description: TAK-792 1250 mg was administered in the morning after a fast.
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Study NCT02448719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 1250 mg placebo
Description: TAK-792 1250 mg placebo was administered in the morning after a fast.
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Study NCT02237053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study NCT05348187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
Study NCT01232556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: 1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 200 mg to 400 mg orally daily
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 300 mg or 600 mg orally twice daily
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Dosage dependent on participant
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on participant
Study NCT01083329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
Study NCT01232556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
Study NCT01232556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab + gemcitabine
Description: rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
Study NCT01232556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab +bendamustine
Description: rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Bedside Physiology study
Description: A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Carotid Body Function Test
Description: Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Room Air Challenge
Description: Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate \[HR\] \< 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Hypoxia Challenge Test
Description: A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of > 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% \< 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped.
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Effects of Nasal Cannula Flow
Description: Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~1. 28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~2. Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~3. Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops.
Study NCT01083329 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: training
Description: the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
Study NCT01083329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotinic acid
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Study NCT01083329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Study NCT03464396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
Study NCT03464396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
Study NCT03464396 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
Study NCT03379636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
Study NCT03379636 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tape
Description: a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
Study NCT03235141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin eye drops by essex
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
Study NCT03235141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eye drops by essex
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
Study NCT03235141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin eye drops
Description: azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
Study NCT03235141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eye drops
Description: azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
Study NCT02818894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Spinal anesthesia administered prior to participant's THA
Study NCT02818894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia administered prior to participant's THA
Study NCT02201316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 50 mg or 100 mg orally twice daily
Study NCT02201316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Study NCT02201316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Study NCT00759707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-N^G monomethyl arginine (L-NMMA)
Description: L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
Study NCT01656876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror box training
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
Study NCT01656876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mesh glove stimulation
Description: The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
Study NCT01656876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional intervention
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
Study NCT02642809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02642809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study NCT02642809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy
Study NCT04086173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics will be administered at night and will consist of 4 capsules
Study NCT04086173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02642809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided biopsy
Study NCT02642809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Study NCT01834027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jazz music
Description: Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
Study NCT01834027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No music
Description: In this group no music will be played in PACU
Study NCT01971645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
Study NCT01971645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
Study NCT01971645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
Study NCT01971645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
Study NCT01971645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
Study NCT03510663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 16mg
Description: OPC-61815 16mg will be intravenously administered once a week.
Study NCT00260078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg orally daily
Study NCT03510663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 32mg
Description: OPC-61815 32mg will be intravenously administered once a week.
Study NCT03510663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg tablet will be administrated once a week.
Study NCT03510663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be intravenously administered once a week.
Study NCT01671436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Meditation and Imagery Therapy
Study NCT02976493 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT03227575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
Study NCT00260078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
Study NCT01629706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens
Description: Commercially marketed silicone hydrogel contact lens
Study NCT06169436 — intervention group
Intervention type: PROCEDURE
Intervention: Nephroureterectomy
Description: Removal of cancer mass by urether and kidney complete resection.